GlassScriptPhysician profile
Habeeb H Arar
NPI 1881857043
$2,955.88
in general payments reported to CMS, 2019-2025
24 companies · $866 in 2025
The $866 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $73.62 · 2021: $169 · 2022: $492 · 2023: $823 · 2024: $339 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,026.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.63 | 2021-2025 | Vraylar, Creon |
| Alkermes, INC. | $344.60 | 2020-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.42 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $228.71 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $177.22 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $161.25 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $160.70 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.30 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $139.55 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $132.80 | 2022-2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $130.99 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Lundbeck LLC | $81.04 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $78.31 | 2020-2025 | Spravato |
| Avanir Pharmaceuticals, INC. | $46.71 | 2022 | |
| Almatica Pharma LLC | $35.34 | 2022-2023 | Sertraline Hcl, Loreev Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $32.36 | 2019 | |
| Braeburn INC. | $24.64 | 2024 | Brixadi |
| Brainsway USA INC | $24.17 | 2022 | |
| Corium, LLC | $23.30 | 2023 | Azstarys |
| Allergan, INC. | $22.48 | 2020 | |
| Indivior INC. | $20.13 | 2023 | Perseris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.83 | 2022 | |
| Novo Nordisk INC | $13.41 | 2023 | |
| Neuronetics, INC. | $8.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habeeb Arar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.